Cargando…
The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study
Lymphoma defines a group of different diseases. This study examined pre-treatment plasma samples from 66 adult patients (aged 20–74) newly diagnosed with any lymphoma subtype, and 96 frequency matched population controls. We used gas chromatography-mass spectrometry (GC-MS) to compare the metabolic...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650891/ https://www.ncbi.nlm.nih.gov/pubmed/31248049 http://dx.doi.org/10.3390/molecules24132367 |
_version_ | 1783438220735807488 |
---|---|
author | Barberini, Luigi Noto, Antonio Fattuoni, Claudia Satta, Giannina Zucca, Mariagrazia Cabras, Maria Giuseppina Mura, Ester Cocco, Pierluigi |
author_facet | Barberini, Luigi Noto, Antonio Fattuoni, Claudia Satta, Giannina Zucca, Mariagrazia Cabras, Maria Giuseppina Mura, Ester Cocco, Pierluigi |
author_sort | Barberini, Luigi |
collection | PubMed |
description | Lymphoma defines a group of different diseases. This study examined pre-treatment plasma samples from 66 adult patients (aged 20–74) newly diagnosed with any lymphoma subtype, and 96 frequency matched population controls. We used gas chromatography-mass spectrometry (GC-MS) to compare the metabolic profile by case/control status and across the major lymphoma subtypes. We conducted univariate and multivariate analyses, and partial least square discriminant analysis (PLS-DA). When compared to the controls, statistically validated models were obtained for diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and Hodgkin lymphoma (HL), but not follicular lymphoma (FL). The metabolomic analysis highlighted interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects: Important metabolites, such as hypoxanthine and elaidic acid, were more abundant in all lymphoma subtypes. The small sample size of the individual lymphoma subtypes prevented obtaining PLS-DA validated models, although specific peculiar features of each subtype were observed; for instance, fatty acids were most represented in MM and HL patients, while 2-aminoadipic acid, 2-aminoheptanedioic acid, erythritol, and threitol characterized DLBCL and CLL. Metabolomic analysis was able to highlight interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects. Further studies are warranted to understand whether the peculiar metabolic patterns observed might serve as early biomarkers of lymphoma. |
format | Online Article Text |
id | pubmed-6650891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66508912019-08-07 The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study Barberini, Luigi Noto, Antonio Fattuoni, Claudia Satta, Giannina Zucca, Mariagrazia Cabras, Maria Giuseppina Mura, Ester Cocco, Pierluigi Molecules Article Lymphoma defines a group of different diseases. This study examined pre-treatment plasma samples from 66 adult patients (aged 20–74) newly diagnosed with any lymphoma subtype, and 96 frequency matched population controls. We used gas chromatography-mass spectrometry (GC-MS) to compare the metabolic profile by case/control status and across the major lymphoma subtypes. We conducted univariate and multivariate analyses, and partial least square discriminant analysis (PLS-DA). When compared to the controls, statistically validated models were obtained for diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and Hodgkin lymphoma (HL), but not follicular lymphoma (FL). The metabolomic analysis highlighted interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects: Important metabolites, such as hypoxanthine and elaidic acid, were more abundant in all lymphoma subtypes. The small sample size of the individual lymphoma subtypes prevented obtaining PLS-DA validated models, although specific peculiar features of each subtype were observed; for instance, fatty acids were most represented in MM and HL patients, while 2-aminoadipic acid, 2-aminoheptanedioic acid, erythritol, and threitol characterized DLBCL and CLL. Metabolomic analysis was able to highlight interesting differences between lymphoma patients and population controls, allowing the discrimination between pathologic and healthy subjects. Further studies are warranted to understand whether the peculiar metabolic patterns observed might serve as early biomarkers of lymphoma. MDPI 2019-06-26 /pmc/articles/PMC6650891/ /pubmed/31248049 http://dx.doi.org/10.3390/molecules24132367 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Barberini, Luigi Noto, Antonio Fattuoni, Claudia Satta, Giannina Zucca, Mariagrazia Cabras, Maria Giuseppina Mura, Ester Cocco, Pierluigi The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study |
title | The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study |
title_full | The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study |
title_fullStr | The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study |
title_full_unstemmed | The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study |
title_short | The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study |
title_sort | metabolomic profile of lymphoma subtypes: a pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650891/ https://www.ncbi.nlm.nih.gov/pubmed/31248049 http://dx.doi.org/10.3390/molecules24132367 |
work_keys_str_mv | AT barberiniluigi themetabolomicprofileoflymphomasubtypesapilotstudy AT notoantonio themetabolomicprofileoflymphomasubtypesapilotstudy AT fattuoniclaudia themetabolomicprofileoflymphomasubtypesapilotstudy AT sattagiannina themetabolomicprofileoflymphomasubtypesapilotstudy AT zuccamariagrazia themetabolomicprofileoflymphomasubtypesapilotstudy AT cabrasmariagiuseppina themetabolomicprofileoflymphomasubtypesapilotstudy AT muraester themetabolomicprofileoflymphomasubtypesapilotstudy AT coccopierluigi themetabolomicprofileoflymphomasubtypesapilotstudy AT barberiniluigi metabolomicprofileoflymphomasubtypesapilotstudy AT notoantonio metabolomicprofileoflymphomasubtypesapilotstudy AT fattuoniclaudia metabolomicprofileoflymphomasubtypesapilotstudy AT sattagiannina metabolomicprofileoflymphomasubtypesapilotstudy AT zuccamariagrazia metabolomicprofileoflymphomasubtypesapilotstudy AT cabrasmariagiuseppina metabolomicprofileoflymphomasubtypesapilotstudy AT muraester metabolomicprofileoflymphomasubtypesapilotstudy AT coccopierluigi metabolomicprofileoflymphomasubtypesapilotstudy |